
Novo makes fresh obesity play with $2.2bn Septerna deal
It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage candidates developed by Septerna. The upfront and near-term …